THE SHORT VERSION
- Stopping, switching or pausing a prescribed medicine is a clinical decision. SlimBee does not publish taper schedules.
Discuss with your prescriber
Ask about monitoring, maintenance options and habit support.
MHRA GLP-1 guidance includes themes on switching — follow personalised advice.
- Write down your current medicines and allergies before any consultation.
- Confirm who prescribes, who dispenses, and how aftercare works.
- Keep screenshots or emails of price, dose and delivery terms at checkout.
- Know how to contact the service if side effects or supply problems arise.
Sources you can check
- MHRA GLP-1 medicines safety guidance
- NICE TA1026 on tirzepatide (Mounjaro)
- NICE TA875 on semaglutide (Wegovy)
Editorial presentation updated 24 October 2026. This is general information, not individual medical advice or a claim of independent clinical review. Read the linked source and the leaflet supplied with your medicine for the full context. Suggest a correction.